NBG 048
Alternative Names: NBG-048Latest Information Update: 30 Jun 2023
Price :
$50 *
At a glance
- Originator NB Health Laboratory
- Class Antipsoriatics; Monoclonal antibodies
- Mechanism of Action Chemokine receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Psoriasis
Most Recent Events
- 02 Jun 2023 NGB 048 is available for licensing as of 02 Jun 2023. https://nbhl.co.jp/partnering/ (NB Health Laboratory pipeline, June 2023)
- 02 Jun 2023 Early research in Psoriasis in Japan (Parenteral) (NB Health Laboratory pipeline, June 2023)